Sign In
Buy XGN
$4.54
-0.280 (-5.81%)
At Close: Jun 03, 2026
Exagen Inc. (XGN) CEO Ron Rocca on Q1 2021 Results - Earnings Call Transcript
08:57pm, Tuesday, 11'th May 2021
Exagen Inc. (XGN) CEO Ron Rocca on Q1 2021 Results - Earnings Call Transcript
Exagen Inc. Reports First Quarter 2021 Results
04:05pm, Tuesday, 11'th May 2021
Quarterly Records: AVISE® CTD Volumes, Ordering Healthcare Providers and Adopters
The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis, prognosis and monitoring of patients with autoimmune diseases The suite of innovative biomarker assays seeks
Exagen Announces New Campaign and Initiatives for Lupus Awareness Month
08:25am, Monday, 03'rd May 2021
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of awa
Exagen to Announce First Quarter 2021 Financial Results on May 11, 2021
04:05pm, Tuesday, 27'th Apr 2021
SAN DIEGO, April 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2021 after
Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases
08:25am, Monday, 29'th Mar 2021
SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten p
Exagen Inc. Announces Pricing of Public Offering of Common Stock
10:01pm, Monday, 22'nd Mar 2021
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of an underwritten public offering of 3,700,00
Exagen Inc. Announces Proposed Public Offering of Common Stock
04:05pm, Monday, 22'nd Mar 2021
SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it intends to offer and sell, subject to market and o
Exagen Inc. (XGN) CEO Ron Rocca on Q4 2020 Results - Earnings Call Transcript
08:55pm, Tuesday, 16'th Mar 2021
Exagen Inc. (XGN) CEO Ron Rocca on Q4 2020 Results - Earnings Call Transcript
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
06:11pm, Tuesday, 16'th Mar 2021
Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.18% and 16.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results
04:05pm, Tuesday, 16'th Mar 2021
Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters Quarterly Records: Revenue, Gross Margin, AVISE® CTD Volumes and Adopters
Exagen Inc. (XGN) Stock Jumps 6.8%: Will It Continue to Soar?
06:50am, Wednesday, 03'rd Mar 2021
Exagen Inc. (XGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 16, 2021
08:00am, Tuesday, 02'nd Mar 2021
SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, will release financial results for the quarter and year ended December 31, 2020 after the
Exagen Inc. to Participate in the Cowen 41st Annual Health Care Conference
04:05pm, Monday, 22'nd Feb 2021
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the Cowen 41st Annual Health Care Conference which tak
